← Back to Calendar

Ebvallo (tabelecleucel)

Atara Biotherapeutics · $ATRA
Priority Review Breakthrough Therapy BLA
PDUFA Date
January 10, 2026
Date Status
99d ago (past)
Review Type
Priority (6 mo)
Filed
March 10, 2025
63%
Baseline PoA
BLA priority review approval rate (prior CRL resubmission penalty applied)
Based on FDA historical approval rates by submission type (2015–2025)
Dynamic PoA
Coming soon
xAI Sentiment

FDA Decision

❌
✗ Complete Response Letter (CRL)
PDUFA date was January 10, 2026

Live Company Data NMS

Updated just now · Data: FMP
Current Price
$5.27 -14.59%
$-0.90 today
Day: $5.25 – $5.55
Market Cap
N/A
Shares out: 8.18M
Float: 5.33M
52-Week Range
$3.92
$19.14
Current price is at 9% of 52-week range
Avg Volume
268K
Beta
-0.33
vs. S&P 500
Sector
Healthcare
Biotechnology
⚠️ Financial data is for informational purposes only. Not investment advice. Prices may be delayed.
Track $ATRA catalysts → get weekly FDA alerts Subscribe Free on Substack →

Indication

Epstein-Barr virus-positive post-transplant lymphoproliferative disease (EBV+ PTLD)

Key Notes

FDA issued second Complete Response Letter (CRL) on January 12, 2026. ALLELE trial data deemed inadequate for approval. BLA resubmission was accepted July 2025 with PDUFA Jan 10, 2026.
⚠️ Not Investment Advice: This information is provided for educational purposes only. PDUFA dates are FDA target action dates, not guaranteed approval dates. The FDA may extend the review period, issue Complete Response Letters, or take unexpected actions. Probability of approval scores are based on historical base rates and do not account for drug-specific factors. Always consult a financial advisor before making investment decisions.

Discussion

Share your analysis, research, or questions about this catalyst. No account required.

Rate limit: 5/hr per email
Loading comments...
← Back to Full Calendar